Key facts
- Craif’s last known valuation is $75.0M (Apr 2022).
- It has raised $42.5M; the latest was Later Stage VC ($22.0M) in Apr 2025.
- Notable investors include Plug and Play Tech Center, MedTech Innovator, Global Brain, Founders Fund, ANRI — 33 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 33 names
- ·Watchlist + deal alerts for Craif
- ·The full record, as it builds
Funding rounds
No funding rounds for Craif are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Craif
Provider of exosome-based liquid biopsy tests intended to provide accurate and painless early cancer detection. The company's bio-platform encapsulates ribonucleic acid and relates to physiological conditions like disease status, enabling research institutions to distinguish cancer from non-cancer samples with high sensitivity and specificity in two cancer types.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2018
- Employees
- 73
- Website
- craif.com/
- Ownership
- Privately Held (backing)
Craif doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Craif shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Craif in its N-PORT filings yet. We sweep new filings monthly.